Skip to main content
Top

27-09-2024 | Hepatocellular Carcinoma | Research

Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis

Authors: Nicole Abedrabbo, Emily Lerner, Eric Lam, Diana Kadi, Haben Dawit, Christian van der Pol, Jean-Paul Salameh, Haresh Naringrekar, Robert Adamo, Mostafa Alabousi, Brooke Levis, An Tang, Ayman Alhasan, Ashwini Arvind, Amit Singal, Brian Allen, Krzysztof Bartnik, Joanna Podgórska, Alessandro Furlan, Roberto Cannella, Marco Dioguardi Burgio, Milena Cerny, Sang Hyun Choi, Christopher Clarke, Xiang Jing, Andrea Kierans, Maxime Ronot, Grzegorz Rosiak, Hanyu Jiang, Ji Soo Song, Caecilia C. Reiner, Ijin Joo, Heejin Kwon, Wentao Wang, Sheng-xiang Rao, Federico Diaz Telli, Federico Piñero, Nieun Seo, Hyo-Jin Kang, Jin Wang, Ji Hye Min, Andreu Costa, Matthew McInnes, Mustafa Bashir

Published in: Abdominal Radiology

Login to get access

Abstract

Background

The Liver Imaging Reporting and Data System (LI-RADS) does not consider factors extrinsic to the observation of interest, such as concurrent LR-5 observations.

Purpose

To evaluate whether the presence of a concurrent LR-5 observation is associated with a difference in the probability that LR-3 or LR-4 observations represent hepatocellular carcinoma (HCC) through an individual participant data (IPD) meta-analysis.

Methods

Multiple databases were searched from 1/2014 to 2/2023 for studies evaluating the diagnostic accuracy of CT/MRI for HCC using LI-RADS v2014/2017/2018. The search strategy, study selection, and data collection process can be found at https://​osf.​io/​rpg8x. Using a generalized linear mixed model (GLMM), IPD were pooled across studies and modeled simultaneously with a one-stage meta-analysis approach to estimate positive predictive value (PPV) of LR-3 and LR-4 observations without and with concurrent LR-5 for the diagnosis of HCC. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2).

Results

Twenty-nine studies comprising 2591 observations in 1456 patients (mean age 59 years, 1083 [74%] male) were included. 587/1960 (29.9%) LR-3 observations in 1009 patients had concurrent LR-5. The PPV for LR-3 observations with concurrent LR-5 was not significantly different from the PPV without LR-5 (45.4% vs 37.1%, p = 0.63). 264/631 (41.8%) LR-4 observations in 447 patients had concurrent LR-5. The PPV for LR-4 observations with concurrent LR-5 was not significantly different from LR-4 observations without concurrent LR-5 (88.6% vs 69.5%, p = 0.08). A sensitivity analysis for low-risk of bias studies (n = 9) did not differ from the primary analysis.

Conclusion

The presence of concurrent LR-5 was not significantly associated with differences in PPV for HCC in LR-3 or LR-4 observations, supporting the current LI-RADS paradigm, wherein the presence of synchronous LR-5 may not alter the categorization of LR-3 and LR-4 observations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology. 2023;20(12):864-84.PubMedCrossRef Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology. 2023;20(12):864-84.PubMedCrossRef
2.
go back to reference Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-63.PubMed Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229-63.PubMed
3.
go back to reference Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7(1):6.PubMedCrossRef Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7(1):6.PubMedCrossRef
4.
go back to reference Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. Journal of Hepatocellular Carcinoma. 2016;3(null):41-53.PubMedPubMedCentralCrossRef Balogh J, Victor D, Asham EH, Burroughs SG, Boktour M, Saharia A, et al. Hepatocellular carcinoma: a review. Journal of Hepatocellular Carcinoma. 2016;3(null):41-53.PubMedPubMedCentralCrossRef
5.
go back to reference Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816-30.PubMedCrossRef Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289(3):816-30.PubMedCrossRef
6.
go back to reference van der Pol CB, Lim CS, Sirlin CB, McGrath TA, Salameh J-P, Bashir MR, et al. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review. Gastroenterology. 2019;156(4):976-86.PubMedCrossRef van der Pol CB, Lim CS, Sirlin CB, McGrath TA, Salameh J-P, Bashir MR, et al. Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy—A Systematic Review. Gastroenterology. 2019;156(4):976-86.PubMedCrossRef
7.
go back to reference Lee T-H, Hirshman N, Cardona DM, Berg CL, Fowler KJ, Bashir MR, et al. LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR–TR Lesions. Digestive Diseases and Sciences. 2022;67:5345 - 52.PubMedCrossRef Lee T-H, Hirshman N, Cardona DM, Berg CL, Fowler KJ, Bashir MR, et al. LR-3 and LR-4 Lesions Are More Likely to Be Hepatocellular Carcinoma in Transplant Patients with LR-5 or LR–TR Lesions. Digestive Diseases and Sciences. 2022;67:5345 - 52.PubMedCrossRef
8.
go back to reference Smereka P, Doshi AM, Lavelle LP, Shanbhogue K. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification. AJR Am J Roentgenol. 2020;215(2):382-9.PubMedCrossRef Smereka P, Doshi AM, Lavelle LP, Shanbhogue K. New Arterial Phase Enhancing Nodules on MRI of Cirrhotic Liver: Risk of Progression to Hepatocellular Carcinoma and Implications for LI-RADS Classification. AJR Am J Roentgenol. 2020;215(2):382-9.PubMedCrossRef
9.
go back to reference Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953;6(5):963-8.PubMed Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin. Cancer. 1953;6(5):963-8.PubMed
10.
go back to reference Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Modern Pathology. 2015;28(1):14-29.PubMedCrossRef Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, et al. Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Modern Pathology. 2015;28(1):14-29.PubMedCrossRef
11.
go back to reference Ranathunga D, Osman H, Islam N, McInnes MDF, Munir J, Pol CBvd, et al. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study. American Journal of Roentgenology. 2022;218(3):462-70.PubMedCrossRef Ranathunga D, Osman H, Islam N, McInnes MDF, Munir J, Pol CBvd, et al. Progression Rates of LR-2 and LR-3 Observations on MRI to Higher LI-RADS Categories in Patients at High Risk of Hepatocellular Carcinoma: A Retrospective Study. American Journal of Roentgenology. 2022;218(3):462-70.PubMedCrossRef
12.
go back to reference Goins SM, Jiang H, Pol CBvd, Salameh J-P, Lam E, Adamo RG, et al. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis. Radiology. 2023;309(3):e231656.PubMedCrossRef Goins SM, Jiang H, Pol CBvd, Salameh J-P, Lam E, Adamo RG, et al. Individual Participant Data Meta-Analysis of LR-5 in LI-RADS Version 2018 versus Revised LI-RADS for Hepatocellular Carcinoma Diagnosis. Radiology. 2023;309(3):e231656.PubMedCrossRef
13.
go back to reference van der Pol CB, McInnes MDF, Salameh JP, Levis B, Chernyak V, Sirlin CB, et al. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. Radiology. 2022;302(2):326-35.PubMedCrossRef van der Pol CB, McInnes MDF, Salameh JP, Levis B, Chernyak V, Sirlin CB, et al. CT/MRI and CEUS LI-RADS Major Features Association with Hepatocellular Carcinoma: Individual Patient Data Meta-Analysis. Radiology. 2022;302(2):326-35.PubMedCrossRef
14.
go back to reference Goins SM, Jiang H, van der Pol CB, Salameh JP, Lam E, Adamo RG, et al. Comparative performance of 2018 LI-RADS versus Modified LIRADS (mLI-RADS): An Individual Participant Data Meta-Analysis. J Magn Reson Imaging. 2024;60(3):1082-91. Goins SM, Jiang H, van der Pol CB, Salameh JP, Lam E, Adamo RG, et al. Comparative performance of 2018 LI-RADS versus Modified LIRADS (mLI-RADS): An Individual Participant Data Meta-Analysis. J Magn Reson Imaging. 2024;60(3):1082-91.
15.
go back to reference Deeks JJ BP, Leeflang MM, Takwoingi Y (editors). . Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023). Cochrane2023. Deeks JJ BP, Leeflang MM, Takwoingi Y (editors). . Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Version 2.0 (updated July 2023). Cochrane2023.
16.
go back to reference McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. Jama. 2018;319(4):388-96.PubMedCrossRef McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement. Jama. 2018;319(4):388-96.PubMedCrossRef
17.
go back to reference American College of Radiology Liver Reporting and Data System (LI-RADS). . American College of Radiology Liver Reporting and Data System (LI-RADS). .
18.
go back to reference Kambadakone AR, Fung A, Gupta RT, Hope TA, Fowler KJ, Lyshchik A, et al. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY). 2018;43(1):56-74.PubMedCrossRef Kambadakone AR, Fung A, Gupta RT, Hope TA, Fowler KJ, Lyshchik A, et al. LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY). 2018;43(1):56-74.PubMedCrossRef
19.
go back to reference Riley RD, Levis B, Takwoingi Y. IPD Meta-Analysis for Test Accuracy Research. Individual Participant Data Meta‐Analysis2021. p. 387-420.CrossRef Riley RD, Levis B, Takwoingi Y. IPD Meta-Analysis for Test Accuracy Research. Individual Participant Data Meta‐Analysis2021. p. 387-420.CrossRef
20.
go back to reference Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, et al. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. Bmj. 2021;372:n265.PubMedPubMedCentralCrossRef Cohen JF, Deeks JJ, Hooft L, Salameh JP, Korevaar DA, Gatsonis C, et al. Preferred reporting items for journal and conference abstracts of systematic reviews and meta-analyses of diagnostic test accuracy studies (PRISMA-DTA for Abstracts): checklist, explanation, and elaboration. Bmj. 2021;372:n265.PubMedPubMedCentralCrossRef
21.
go back to reference Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software. 2015;67(1):1 - 48.CrossRef Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software. 2015;67(1):1 - 48.CrossRef
22.
go back to reference Kanneganti M, Marrero JA, Parikh ND, Kanwal F, Yokoo T, Mendiratta-Lala M, et al. Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review. Liver Transpl. 2022;28(12):1865-75.PubMedPubMedCentralCrossRef Kanneganti M, Marrero JA, Parikh ND, Kanwal F, Yokoo T, Mendiratta-Lala M, et al. Clinical outcomes of patients with Liver Imaging Reporting and Data System 3 or Liver Imaging Reporting and Data System 4 observations in patients with cirrhosis: A systematic review. Liver Transpl. 2022;28(12):1865-75.PubMedPubMedCentralCrossRef
23.
go back to reference De Muzio F, Grassi F, Dell'Aversana F, Fusco R, Danti G, Flammia F, et al. A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. Diagnostics (Basel). 2022;12(7). De Muzio F, Grassi F, Dell'Aversana F, Fusco R, Danti G, Flammia F, et al. A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls. Diagnostics (Basel). 2022;12(7).
24.
go back to reference Mettikanont P, Kalluri A, Bittermann T, Phillips N, Loza BL, Rosen M, et al. The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated With Explant Pathology: A Single Center Experience. J Clin Exp Hepatol. 2022;12(4):1048-56.PubMedPubMedCentralCrossRef Mettikanont P, Kalluri A, Bittermann T, Phillips N, Loza BL, Rosen M, et al. The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated With Explant Pathology: A Single Center Experience. J Clin Exp Hepatol. 2022;12(4):1048-56.PubMedPubMedCentralCrossRef
25.
go back to reference Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6). Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6).
26.
go back to reference Kim Y-Y, Choi J-Y, Kim SU, Lee M, Park M-S, Chung YE, et al. MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy. American Journal of Roentgenology. 2020;215(6):1354-62.PubMedCrossRef Kim Y-Y, Choi J-Y, Kim SU, Lee M, Park M-S, Chung YE, et al. MRI Ancillary Features for LI-RADS Category 3 and 4 Observations: Improved Categorization to Indicate the Risk of Hepatic Malignancy. American Journal of Roentgenology. 2020;215(6):1354-62.PubMedCrossRef
27.
go back to reference Alhasan A, Cerny M, Olivié D. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol. 2019;44(2):517-28.CrossRef Alhasan A, Cerny M, Olivié D. LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol. 2019;44(2):517-28.CrossRef
28.
go back to reference Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. American Journal of Roentgenology. 2018;210(6):1266-72.PubMedCrossRef Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. American Journal of Roentgenology. 2018;210(6):1266-72.PubMedCrossRef
29.
go back to reference Arvind A, Joshi S, Zaki T. Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. Clinical Gastroenterology and Hepatology. 2023;21(4):1091-3.PubMedCrossRef Arvind A, Joshi S, Zaki T. Risk of Hepatocellular Carcinoma in Patients With Indeterminate (LI-RADS 3) Liver Observations. Clinical Gastroenterology and Hepatology. 2023;21(4):1091-3.PubMedCrossRef
30.
go back to reference Cannella R, Dioguardi Burgio M, Beaufrère A. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. JHEP Reports. 2021;3(6).CrossRef Cannella R, Dioguardi Burgio M, Beaufrère A. Imaging features of histological subtypes of hepatocellular carcinoma: Implication for LI-RADS. JHEP Reports. 2021;3(6).CrossRef
31.
go back to reference Bartnik K, Podgórska J, Rosiak G, Korzeniowski K, Rowiński O. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization. Abdom Radiol. 2022;47(1):115-22.CrossRef Bartnik K, Podgórska J, Rosiak G, Korzeniowski K, Rowiński O. Inter-observer agreement using the LI-RADS version 2018 CT treatment response algorithm in patients with hepatocellular carcinoma treated with conventional transarterial chemoembolization. Abdom Radiol. 2022;47(1):115-22.CrossRef
32.
go back to reference Cerny M, Bergeron C, Billiard JS. LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features. Radiology. 2018;288(1):118-28.PubMedCrossRef Cerny M, Bergeron C, Billiard JS. LI-RADS for MR Imaging Diagnosis of Hepatocellular Carcinoma: Performance of Major and Ancillary Features. Radiology. 2018;288(1):118-28.PubMedCrossRef
33.
go back to reference Kim DH, Choi SH, Byun JH. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. Journal of Hepatology. 2019;71(3):534-42.PubMedCrossRef Kim DH, Choi SH, Byun JH. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. Journal of Hepatology. 2019;71(3):534-42.PubMedCrossRef
34.
go back to reference Lee C, Choi SH, Byun JH. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Hepatol Int. 2021;15(3):676-84.PubMedCrossRef Lee C, Choi SH, Byun JH. Combined computed tomography and magnetic resonance imaging improves diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Hepatol Int. 2021;15(3):676-84.PubMedCrossRef
35.
go back to reference Choi JY, Ha J, Choi SH, Kang HJ, Kim SY, Kim KW. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification. Abdom Radiol. 2022;47(3):1024-31.CrossRef Choi JY, Ha J, Choi SH, Kang HJ, Kim SY, Kim KW. Comparison of gadoxetate disodium-enhanced MRI sequences for measuring hepatic observation size and its implication of LI-RADS classification. Abdom Radiol. 2022;47(3):1024-31.CrossRef
36.
go back to reference Choi SJ, Choi SH, Kim DW. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS. Journal of Hepatology. 2023;78(3):596-603.PubMedCrossRef Choi SJ, Choi SH, Kim DW. Value of threshold growth as a major diagnostic feature of hepatocellular carcinoma in LI-RADS. Journal of Hepatology. 2023;78(3):596-603.PubMedCrossRef
37.
go back to reference Clarke CGD, Albazaz R, Smith CR. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. Clinical Radiology. 2021;76(5):333-41.PubMedCrossRef Clarke CGD, Albazaz R, Smith CR. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. Clinical Radiology. 2021;76(5):333-41.PubMedCrossRef
38.
go back to reference Cannella R, Vernuccio F, Sagreiya H. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol. 2020;30(7):3770-81.PubMedCrossRef Cannella R, Vernuccio F, Sagreiya H. Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol. 2020;30(7):3770-81.PubMedCrossRef
39.
go back to reference Jiang H, Song B, Qin Y. Data‐Driven Modification of the LI‐RADS Major Feature System on Gadoxetate Disodium‐Enhanced MRI : Toward Better Sensitivity and Simplicity. Magnetic Resonance Imaging. 2022;55(2):493-506.CrossRef Jiang H, Song B, Qin Y. Data‐Driven Modification of the LI‐RADS Major Feature System on Gadoxetate Disodium‐Enhanced MRI : Toward Better Sensitivity and Simplicity. Magnetic Resonance Imaging. 2022;55(2):493-506.CrossRef
40.
go back to reference Ding J, Long L, Zhang X. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Eur Radiol. 2021;31(2):847-54.PubMedCrossRef Ding J, Long L, Zhang X. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Eur Radiol. 2021;31(2):847-54.PubMedCrossRef
41.
go back to reference Jeon SK, Joo I, Bae JS, Park SJ, Lee JM. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid–enhanced MRI. Eur Radiol. 2022;32(1):46-55.PubMedCrossRef Jeon SK, Joo I, Bae JS, Park SJ, Lee JM. LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid–enhanced MRI. Eur Radiol. 2022;32(1):46-55.PubMedCrossRef
42.
go back to reference Kang HJ, Lee JM, Jeon SK. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid–enhanced liver MRI. Eur Radiol. 2021;31(2):824-33.PubMedCrossRef Kang HJ, Lee JM, Jeon SK. Intra-individual comparison of dual portal venous phases for non-invasive diagnosis of hepatocellular carcinoma at gadoxetic acid–enhanced liver MRI. Eur Radiol. 2021;31(2):824-33.PubMedCrossRef
43.
go back to reference Kierans AS, Makkar J, Guniganti P. Validation of Liver Imaging Reporting and Data System 2017 (LI‐RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma. Magnetic Resonance Imaging. 2019;49(7). Kierans AS, Makkar J, Guniganti P. Validation of Liver Imaging Reporting and Data System 2017 (LI‐RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma. Magnetic Resonance Imaging. 2019;49(7).
44.
go back to reference Lim K, Kwon H, Cho J, Kim D, Kang E, Kim S. Added value of enhanced CT on LR-3 and LR-4 observation of Gd-EOB-DTPA MRI for the diagnosis of HCC: are CT and MR washout features interchangeable? BJR. 2022;95(1132).CrossRef Lim K, Kwon H, Cho J, Kim D, Kang E, Kim S. Added value of enhanced CT on LR-3 and LR-4 observation of Gd-EOB-DTPA MRI for the diagnosis of HCC: are CT and MR washout features interchangeable? BJR. 2022;95(1132).CrossRef
45.
go back to reference Min JH, Kim JM, Kim YK. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Eur Radiol. 2022;32(2):912-22.PubMedCrossRef Min JH, Kim JM, Kim YK. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Eur Radiol. 2022;32(2):912-22.PubMedCrossRef
46.
go back to reference Piñero F, Thompson MA, Diaz Telli F. LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. Annals of Hepatology. 2020;19(6):662-7.PubMedCrossRef Piñero F, Thompson MA, Diaz Telli F. LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. Annals of Hepatology. 2020;19(6):662-7.PubMedCrossRef
47.
go back to reference Ronot M, Fouque O, Esvan M, Lebigot J, Aubé C, Vilgrain V. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm. Journal of Hepatology. 2018;68(4):715-23.PubMedCrossRef Ronot M, Fouque O, Esvan M, Lebigot J, Aubé C, Vilgrain V. Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3 cm. Journal of Hepatology. 2018;68(4):715-23.PubMedCrossRef
48.
go back to reference Paisant A, Vilgrain V, Riou J. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. Journal of Hepatology. 2020;72(5):937-45.PubMedCrossRef Paisant A, Vilgrain V, Riou J. Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. Journal of Hepatology. 2020;72(5):937-45.PubMedCrossRef
49.
go back to reference Rosiak G, Podgorska J, Rosiak E, Cieszanowski A. Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents. BioMed Research International. 2018;2018:1-6.CrossRef Rosiak G, Podgorska J, Rosiak E, Cieszanowski A. Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents. BioMed Research International. 2018;2018:1-6.CrossRef
50.
go back to reference Seo N, Kim MS, Park MS. Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation. Eur Radiol. 2019;29(2):1022-31.PubMedCrossRef Seo N, Kim MS, Park MS. Optimal criteria for hepatocellular carcinoma diagnosis using CT in patients undergoing liver transplantation. Eur Radiol. 2019;29(2):1022-31.PubMedCrossRef
51.
go back to reference Song JS, Choi EJ, Hwang SB, Hwang HP, Choi H. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol. 2019;29(1):401-10.PubMedCrossRef Song JS, Choi EJ, Hwang SB, Hwang HP, Choi H. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol. 2019;29(1):401-10.PubMedCrossRef
52.
go back to reference Stocker D, Becker AS, Barth BK. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018–based classification of liver lesions? Eur Radiol. 2020;30(5):2922-33.PubMedCrossRef Stocker D, Becker AS, Barth BK. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018–based classification of liver lesions? Eur Radiol. 2020;30(5):2922-33.PubMedCrossRef
53.
go back to reference Pol CBvd, Dhindsa K, Shergill R, Zha N, Ferri M, Kagoma YK, et al. MRI LI-RADS Version 2018: Impact of and Reduction in Ancillary Features. American Journal of Roentgenology. 2021;216(4):935-42.PubMedCrossRef Pol CBvd, Dhindsa K, Shergill R, Zha N, Ferri M, Kagoma YK, et al. MRI LI-RADS Version 2018: Impact of and Reduction in Ancillary Features. American Journal of Roentgenology. 2021;216(4):935-42.PubMedCrossRef
54.
go back to reference Wang W, Yang C, Zhu K, Yang L, Ding Y, Luo R, et al. Recurrence After Curative Resection of Hepatitis B Virus–Related Hepatocellular Carcinoma: Diagnostic Algorithms on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging. Liver Transplantation. 2020;26(6):751-63.PubMedCrossRef Wang W, Yang C, Zhu K, Yang L, Ding Y, Luo R, et al. Recurrence After Curative Resection of Hepatitis B Virus–Related Hepatocellular Carcinoma: Diagnostic Algorithms on Gadoxetic Acid–Enhanced Magnetic Resonance Imaging. Liver Transplantation. 2020;26(6):751-63.PubMedCrossRef
55.
go back to reference Zhang L, Kuang S, Chen J. The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection. Front Oncol. 2019;9(1336). Zhang L, Kuang S, Chen J. The Role of Preoperative Dynamic Contrast-enhanced 3.0-T MR Imaging in Predicting Early Recurrence in Patients With Early-Stage Hepatocellular Carcinomas After Curative Resection. Front Oncol. 2019;9(1336).
Metadata
Title
Is concurrent LR-5 associated with a higher rate of hepatocellular carcinoma in LR-3 or LR-4 observations? An individual participant data meta-analysis
Authors
Nicole Abedrabbo
Emily Lerner
Eric Lam
Diana Kadi
Haben Dawit
Christian van der Pol
Jean-Paul Salameh
Haresh Naringrekar
Robert Adamo
Mostafa Alabousi
Brooke Levis
An Tang
Ayman Alhasan
Ashwini Arvind
Amit Singal
Brian Allen
Krzysztof Bartnik
Joanna Podgórska
Alessandro Furlan
Roberto Cannella
Marco Dioguardi Burgio
Milena Cerny
Sang Hyun Choi
Christopher Clarke
Xiang Jing
Andrea Kierans
Maxime Ronot
Grzegorz Rosiak
Hanyu Jiang
Ji Soo Song
Caecilia C. Reiner
Ijin Joo
Heejin Kwon
Wentao Wang
Sheng-xiang Rao
Federico Diaz Telli
Federico Piñero
Nieun Seo
Hyo-Jin Kang
Jin Wang
Ji Hye Min
Andreu Costa
Matthew McInnes
Mustafa Bashir
Publication date
27-09-2024
Publisher
Springer US
Published in
Abdominal Radiology
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-024-04580-6

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more